Evidence map›Paper›PMID 30621212›Full record

ReviewJournal of clinical medicine2019

Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Tamara Y Milder, Sophie L Stocker, Christina Abdel Shaheed, Lucy McGrath-Cadell, Dorit Samocha-Bonet, Jerry R Greenfield, Richard O Day

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tamara Y MilderDepartment of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, NSW 2010, Australia. t.milder@unsw.edu.au.
Sophie L StockerDepartment of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, NSW 2010, Australia. sophie.stocker@svha.org.au.
Christina Abdel ShaheedSchool of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia. christina.abdelshaheed@sydney.edu.au.
Lucy McGrath-CadellSt. Vincent's Clinical School, University of NSW, Sydney, NSW 2010, Australia. lucy.mcgrath-cadell@svha.org.au.
Dorit Samocha-BonetSt. Vincent's Clinical School, University of NSW, Sydney, NSW 2010, Australia. d.samochabonet@garvan.org.au.ORCID 0000-0001-9422-7852
Jerry R GreenfieldDepartment of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, NSW 2010, Australia. j.greenfield@garvan.org.au.
Richard O DayDepartment of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, NSW 2010, Australia. r.day@unsw.edu.au.ORCID 0000-0002-6045-6937
Garvan Institute of Medical Research · AUSt Vincent's Hospital Sydney · AUSt Vincent's Hospital Melbourne · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGuidelines differ with regard to indications for initial combination pharmacotherapy for type 2 diabetes.

aimsTo compare the efficacy and safety of (i) sodium-glucose cotransporter 2 (SGLT2) inhibitor combination therapy in treatment-naïve type 2 diabetes adults; (ii) initial high and low dose SGLT2 inhibitor combination therapy.

methodsPubMed, Embase and Cochrane Library were searched for randomised controlled trials (RCTs) of initial SGLT2 combination therapy. Mean difference (MD) for changes from baseline (HbA1c, weight, blood pressure) after 24⁻26 weeks of treatment and relative risks (RR, safety) were calculated using a random-effects model. Risk of bias and quality of evidence was assessed.

resultsIn 4 RCTs (

conclusionsInitial SGLT2 inhibitor/metformin combination therapy has glycaemic and weight benefits compared with either agent alone and appears relatively safe. High dose SGLT2 inhibitor/metformin combination therapy appears to have modest weight, but no glycaemic benefits compared with the low dose combination therapy.

Indexed as

clinical pharmacologyDPP-4 inhibitorsmetforminpharmacotherapySGLT2 inhibitorstype 2 diabetes

Identifiers

PMID30621212
PMCPMC6352265
OpenAlexW2907263162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.